UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File Number: 001-42549 Kestra Medical Technologies, Ltd. (Exact Name of Registrant as Specified in its Charter) | Bermuda | Not Applicable ...

Kestra Medical Technologies (NasdaqGS:KMTS) Q1 2026 Earnings Call September 11, 2025 04:30 PM ET Company ParticipantsVaseem Mahboob - CFONeil Bhalodkar - VP of Investor RelationsBrian Webster - President and CEOConference Call ParticipantsMike Pollock - AnalystDaniel Downes - AnalystTravis Steed - AnalystLawrence Biegelsen - AnalystMatthew O'Brien - AnalystRick Wise - AnalystOperatorAfternoon and welcome to the Kestra Medical Technologies Earnings Conference Call. This conference call is being recorded for ...

Kestra Medical Technologies (NasdaqGS:KMTS) Q1 2026 Earnings Call September 11, 2025 04:30 PM ET Company ParticipantsVaseem Mahboob - CFONeil Bhalodkar - VP of Investor RelationsBrian Webster - President and CEOConference Call ParticipantsMike Pollock - AnalystDaniel Downes - AnalystTravis Steed - AnalystLawrence Biegelsen - AnalystMatthew O'Brien - AnalystRick Wise - AnalystOperatorAfternoon and welcome to the Kestra Medical Technologies earnings conference call. This conference call is being recorded for ...

Kestra Medical Technologies (NasdaqGS:KMTS) Q1 2026 Earnings Call September 11, 2025 04:30 PM ET Speaker2Afternoon and welcome to the Kestra Medical Technologies earnings conference call. This conference call is being recorded for replay purposes. We will be facilitating a question and answer session following prepared remarks from management. At this time, all participants are in listen-only mode. I would now like to turn the call over to Neil Bhalodkar, Vice President of Investor Relations, for introducto ...

Exhibit 99.1 Kestra Medical Technologies Reports First Quarter Fiscal 2026 Financial Results KIRKLAND, Wash., September 11, 2025 (GLOBE NEWSWIRE) — Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today reported financial results for the first quarter fiscal 2026, which ended July 31, 2025. Financial Highlights First Quarter Fiscal 2026 Financial Results *Adjusted EBITDA is a non-GAAP financial measure. See "Use of Non-GAAP Financial Measures" below ...

KIRKLAND, Wash., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today reported financial results for the first quarter fiscal 2026, which ended July 31, 2025. Financial Highlights Generated revenue of $19.4 million in Q1 FY26, an increase of 52% compared to the prior year period.Expanded gross margin to 45.7% in Q1 FY26 compared to 32.9% in the prior year period.Increased FY26 revenue guidance to $88 million, rep ...

KIRKLAND, Wash., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today announced that it will report first quarter fiscal 2026 financial results on Thursday, September 11. Management will host a corresponding conference call at 4:30 p.m. Eastern Time. A live and archived webcast of the conference call will be available in the “Events” section of the investor relations website. Participants are encouraged to registe ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-42549 Kestra Medical Technologies, Ltd. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of incorporation or organization) 3933 Lake Was ...

Company Overview - Kestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease through monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected [5] Industry Recognition - Kestra Medical Technologies has been recognized as a 2025 Top Workplaces Industry winner by Energage, highlighting its commitment to building a people-first workplace culture [1][2] - The Top Workplaces award is based on feedback from a research-backed employee engagement survey, emphasizing the importance of employee voice and engagement in the workplace [3][4] Leadership Perspective - The recognition as a Top Workplace reflects the dedication of Kestra's team members and their commitment to the company's mission of empowering providers and improving patient outcomes [3] - The CEO of Energage stated that earning a Top Workplaces award is a badge of honor for companies, as it comes authentically from their employees, which is crucial in today's market [4]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $17.2 million, representing a 71% increase year-over-year [9][24] - For fiscal year 2025, total revenue reached $59.8 million, a 115% increase compared to fiscal year 2024 [24] - Gross margin improved to 44.3% in Q4 2025 from 13.9% in the prior year [10][25] - Fiscal year 2025 gross margin was 40.5%, up from 1.3% in fiscal year 2024 [11][25] - GAAP net loss for Q4 2025 was $51.1 million, compared to a loss of $22.3 million in the prior year [29] - Adjusted EBITDA loss for Q4 2025 was $20.3 million, compared to a loss of $16.5 million in the prior year [29] Business Line Data and Key Metrics Changes - The Assure system generated over 3,900 prescriptions in Q4 2025, a 43% increase year-over-year [9] - Revenue growth was driven by a higher mix of in-network patients and improvements in revenue cycle management capabilities [24][25] Market Data and Key Metrics Changes - Covered lives for the Assure system now total over 285 million health plan members in the U.S. [13] - The company is targeting geographies with high volumes of WCD prescriptions and strong in-network payer coverage [12] Company Strategy and Development Direction - The company aims to expand its commercial team and enhance revenue cycle management capabilities [11][12] - Plans to nearly double sales coverage over the next few years, increasing from approximately 80 sales territories [12] - The company is focused on continuous innovation and has over 365 patent assets [14][15] - The goal is to make the Assure system the standard of care for patients at risk of sudden cardiac arrest [23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving significant operating leverage and gross margin expansion over the next few years [11][30] - The company expects revenue of $85 million for fiscal year 2026, a 42% increase compared to fiscal year 2025 [30] - Management highlighted the underutilization of WCD therapy, indicating a significant market opportunity [16][17] Other Important Information - The company is not subject to competitive bidding due to the Assure system being a class III medical device [26] - The company is focused on building clinical evidence to support the safety and efficacy of the Assure system [15][84] Q&A Session Summary Question: Guidance for fiscal year 2026 and underlying assumptions - Management indicated that revenue growth will be driven by sales territory productivity, expansion plans, and penetration of existing accounts [33][35] Question: Margin expansion potential - Management noted that margin expansion is expected due to increasing volumes and improved revenue per fit [37][38] Question: Sole source contract with a provider network - Management explained that the contract allows for better patient management and smoother revenue cycle processes [40][42] Question: Seasonality considerations for fiscal year 2026 - Management stated that prescription growth is expected to average 40% per quarter, with higher conversion rates in the first half of the year [44][45] Question: Competitive response and guidance - Management clarified that the guidance reflects normal scaling and territory ramp-up, with no significant competitive issues [48][50] Question: Conversion rate drivers - Management identified fill rate, claim conversion, and in-network patient mix as key drivers of the conversion rate [59][61] Question: Plans for randomized trials - Management is focused on executing the post-approval study and leveraging the data from the registry [83][85]